BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26454663)

  • 1. Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.
    Habte HH; Banerjee S; Shi H; Qin Y; Cho MW
    Virology; 2015 Dec; 486():187-97. PubMed ID: 26454663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.
    Banerjee S; Shi H; Habte HH; Qin Y; Cho MW
    Virology; 2016 Mar; 490():17-26. PubMed ID: 26803471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
    Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
    Virology; 2017 May; 505():113-126. PubMed ID: 28237764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigp41 membrane proximal external region antibodies and the art of using the membrane for neutralization.
    Cerutti N; Loredo-Varela JL; Caillat C; Weissenhorn W
    Curr Opin HIV AIDS; 2017 May; 12(3):250-256. PubMed ID: 28422789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
    Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.
    Dawood R; Benjelloun F; Pin JJ; Kone A; Chanut B; Jospin F; Lucht F; Verrier B; Moog C; Genin C; Paul S
    AIDS; 2013 Mar; 27(5):717-30. PubMed ID: 23719346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
    Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
    Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.
    Benen TD; Tonks P; Kliche A; Kapzan R; Heeney JL; Wagner R
    J Biomed Sci; 2014 Aug; 21(1):79. PubMed ID: 25160824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
    Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Antibodies Targeting HIV-1 gp41.
    Caillat C; Guilligay D; Sulbaran G; Weissenhorn W
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33114242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.
    Melnychuk L; Ajamian L; Jean-Pierre P; Liang J; Gheorghe R; Wainberg MA; Zaharatos GJ
    Vaccine; 2017 May; 35(20):2736-2744. PubMed ID: 28392143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.
    Chen J; Frey G; Peng H; Rits-Volloch S; Garrity J; Seaman MS; Chen B
    J Virol; 2014 Jan; 88(2):1249-58. PubMed ID: 24227838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
    Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
    EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure of the HIV-1 broadly neutralizing antibody 10E8 MPER epitope on the membrane surface by gp41 transmembrane domain scaffolds.
    Oakes V; Torralba J; Rujas E; Nieva JL; Domene C; Apellaniz B
    Biochim Biophys Acta Biomembr; 2018 Jun; 1860(6):1259-1271. PubMed ID: 29477358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.
    Vassell R; He Y; Vennakalanti P; Dey AK; Zhuang M; Wang W; Sun Y; Biron-Sorek Z; Srivastava IK; LaBranche CC; Montefiori DC; Barnett SW; Weiss CD
    PLoS One; 2015; 10(6):e0128562. PubMed ID: 26087072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.
    Liu H; Su X; Si L; Lu L; Jiang S
    Protein Cell; 2018 Jul; 9(7):596-615. PubMed ID: 29667004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.
    Wahome N; Pfeiffer T; Ambiel I; Yang Y; Keppler OT; Bosch V; Burkhard P
    Chem Biol Drug Des; 2012 Sep; 80(3):349-57. PubMed ID: 22650354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topological analysis of the gp41 MPER on lipid bilayers relevant to the metastable HIV-1 envelope prefusion state.
    Wang Y; Kaur P; Sun ZJ; Elbahnasawy MA; Hayati Z; Qiao ZS; Bui NN; Chile C; Nasr ML; Wagner G; Wang JH; Song L; Reinherz EL; Kim M
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22556-22566. PubMed ID: 31624123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.